Myocet Liposomal (Doxorubicin Hydrochloride)

Myocet Liposomal, an anthracycline antibiotic, is used in oncologic regimens targeting solid tumours and hematologic malignancies.

• Metastatic breast cancer: improves disease control and overall survival when combined with standard chemotherapy protocols.
• Ovarian cancer: incorporated into combination therapy for advanced or recurrent disease to enhance tumour response.
• Multiple myeloma: administered in relapsed or refractory settings to achieve reduction of malignant plasma cells.

• Doxorubicin hydrochloride intercalates between DNA base pairs, blocking replication and transcription. It also inhibits topoisomerase II, preventing DNA religation and causing double‑strand breaks. The liposomal carrier enhances delivery to tumour tissue while reducing systemic exposure, and the drug generates free radicals that further damage cellular components, leading to apoptosis of rapidly dividing cancer cells. These mechanisms collectively result in potent cytotoxic activity against malignant cells.

Myocet Liposomal may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset commonly reported during infusion.
• Fatigue: persistent tiredness affecting daily activities.
• Myelosuppression: decreased blood cell counts leading to anemia, neutropenia, or thrombocytopenia.
• Alopecia: temporary hair loss during treatment cycles.

Serious or Rare Side Effects

• Cardiotoxicity: reduced left ventricular ejection fraction or heart failure, especially with cumulative dosing.
• Severe infusion reactions: fever, chills, hypotension, or anaphylaxis requiring immediate medical attention.
• Secondary malignancies: rare risk of therapy‑related leukemias.
• Pulmonary toxicity: interstitial pneumonitis or fibrosis in rare cases.

Prior to initiating Myocet Liposomal therapy, clinicians should observe several precautionary measures to minimize risks.

• Cardiac monitoring: assess baseline and periodic left ventricular ejection fraction due to potential cardiotoxicity.
• Hepatic function: evaluate liver enzymes before treatment and monitor for hepatotoxicity.
• Myelosuppression: perform complete blood counts regularly to detect anemia, neutropenia, or thrombocytopenia.
• Infusion reactions: observe patients during administration for signs of hypersensitivity and be prepared to intervene.
• Pregnancy and lactation: avoid use unless benefits outweigh risks; discuss with specialist and consider contraception.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Myocet Liposomal can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concurrent cardiotoxic agents (e.g., trastuzumab, cyclophosphamide): increased risk of heart damage.
• Live vaccines: immunosuppression may lead to uncontrolled infection.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic exposure and toxicity.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): enhanced bleeding tendency; monitor coagulation parameters.
• Radiation therapy: combined treatment may exacerbate tissue injury.
• Nephrotoxic drugs (e.g., cisplatin): monitor renal function for additive toxicity.
• Antiemetics containing metoclopramide: may affect drug clearance; adjust dosing if needed.